DSM Biologics to manufacture Morphosys antibody
This article was originally published in Scrip
DSM Biologics is to manufacture Morphosys's fully human HuCAL antibody MOR202, a promising target for the treatment of multiple myeloma. The two firms have signed a biopharmaceutical manufacturing agreement covering process development and cGMP manufacturing of MOR202, though no financial details were disclosed. DSM Biologics will manufacture the compound in its cGMP facilities in Groningen, the Netherlands. DSM Biologics also manufactures Morphosys's MOR103, which targets inflammation. Morphosys will continue to use Crucell's PER C6 technology platform for the large-scale manufacture of biopharmaceuticals.
You may also be interested in...
Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.
A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.
Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.